Jamie Miller, APRN
Family · Madisonville, KYNPI 1184646630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,146 of the $18,424 with a category attached, or 82.2%. 32 manufacturers reported payments, led by Mannkind Corporation at 25.0% of the total. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 915 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$5K
- Medtronic$3K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Bayer$1K
- Corcept Therapeutics$1K
- plus $6K from 26 others
What the payments were for
- Consulting fees$7964%
- Travel & lodging$2,41113%
- Food & beverage$15,14682%
- Education$110%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 173 | $4,599 |
| Medtronic | 86 | $2,864 |
| Novo Nordisk | 107 | $1,646 |
| Boehringer Ingelheim | 69 | $1,107 |
| Bayer | 48 | $1,003 |
| Corcept Therapeutics | 58 | $1,001 |
| Lilly USA, LLC | 63 | $964 |
| Insulet Corporation | 50 | $717 |
| Abbott | 33 | $652 |
| Tandem Diabetes Care, Inc. | 32 | $624 |
| Sanofi-aventis U.S. LLC | 38 | $605 |
| Novartis | 25 | $396 |
| AbbVie | 22 | $376 |
| Amgen(2 entities) | 20 | $371 |
| BETA Bionics, Inc. | 19 | $367 |
| AstraZeneca(2 entities) | 14 | $222 |
| Kyowa Kirin, Inc. | 7 | $124 |
| Radius Health, Inc. | 7 | $118 |
| Amarin Pharma, Inc. | 8 | $111 |
| Astellas Pharma US Inc | 6 | $105 |
| Dexcom, Inc. | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 5 | $72 |
| Ascendis Pharma Endocrinology Inc | 4 | $68 |
| Merck | 3 | $45 |
| Amryt Pharma Holdings Ltd | 3 | $35 |
| Clarus Therapeutics Inc. | 3 | $35 |
| Pfizer | 2 | $27 |
| IBSA Pharma Inc. | 2 | $26 |
| Averitas Pharma Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$2,083
- MINIMED 780G$1,379
- Kerendia$330
How this compares
$18,424 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 621 | $719,731 |
| MounjaroTirzepatide | 581 | $690,317 |
| TrulicityDulaglutide | 378 | $437,702 |
| JardianceEmpagliflozin | 353 | $317,876 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 306 | $285,937 |
| Tresiba Flextouch U-100Insulin Degludec | 222 | $122,814 |
| Humulin R U-500Insulin Regular, Human | 79 | $112,699 |
| Novolog FlexpenInsulin Aspart | 398 | $109,843 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 124 | $106,665 |
| FarxigaDapagliflozin Propanediol | 176 | $106,525 |
| AfrezzaInsulin Regular, Human | 29 | $93,351 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $93,019 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 91 | $87,925 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 53 | $81,687 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $77,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $964 | $1,181,9791,089 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $1,646 | $913,507889 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $1,107 | $393,959413 claims |
| AstraZenecaFarxiga | $222 | $106,525176 claims |
| Mannkind CorporationAfrezza | $4,599 | $93,35129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $605 | $87,92591 claims |
| MerckJanuvia | $45 | $65,24593 claims |
| BayerKerendia | $1,003 | $46,90245 claims |
| AbbVieSynthroid | $376 | $12,747186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Madisonville
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.